Influenza virus host resistance model

Methods

Volumn 41, Issue 1, 2007, Pages 31-37

  Burleson, Gary R ^a   Burleson, Florence G ^a  

^a BRT Burleson Research Technologies Inc   (United States)

Author keywords

Cytotoxic T lymphocyte (CTL) activity; Host resistance (HR) models; Influenza virus; Natural killer (NK) cell activity; T Dependent antibody response (TDAR)

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; INTERFERON ANTIBODY;

ARTICLE; CELL ACTIVITY; CELL FUNCTION; CLEARANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; FUNCTIONAL ASSESSMENT; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOLOGICAL MONITORING; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; INFECTION; INFLUENZA VIRUS; INNATE IMMUNITY; INTERFERON PRODUCTION; MACROPHAGE; MICROORGANISM; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; TUMOR CELL; VIRUS INFECTION; VIRUS RESISTANCE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; INFLUENZA, HUMAN;

ORTHOMYXOVIRIDAE;

EID: 33845205013     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2006.09.007     Document Type: Article

References (72)

1. Gleichmann E., Kimber I., and Purchase I.F.H. Arch. Toxicol. 63 (1989) 257-273
2. Burleson G.R. Pulmonary immunocompetence and pulmonary immunotoxicology. In: Smialowicz R., and Holsapple M.P. (Eds). Experimental Immunotoxicology (1996), CRC Press, Inc., Boca Raton, Florida 113-135 Chapter 7
3. Germolec D.R. Toxicol. Lett. 149 (2004) 109-114
4. Burleson G.R., and Dean J.H. Immunotoxicology: Past, present, and future. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), Wiley-Liss Inc., New York, N.Y. 3-10 Volume 1, Chapter 1
5. Burleson G.R. Influenza virus host resistance model for assessment of immunotoxicity, immunostimulation, and antiviral compounds. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), Wiley-Liss Inc., New York, NY 181-202 Volume 2, Chapter 14
6. Burleson G.R. Immunopharmacology 48 (2000) 315-318
7. Bradley S.G. Streptococcus host resistance model. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), WileyLiss Inc., New York, N.Y. 159-168 Chapter 12
8. Gilmour M.I., Park P., and Selgrade M.K. Am. Rev. Respir. Dis. 147 (1993) 753-760
9. Gilmour M.I., and Selgrade M.K. Toxicol. Appl. Pharmacol. 123 (1993) 211-218
10. Takashima K., Tateda K., Matsumoto T., Iizawa Y., Nakao M., and Yamaguchi K. Infect. Immun. 65 (1997) 257-260
11. Bradley S.G. Listeria host resistance model. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), Wiley Liss Inc., New York, N.Y. 169-179 Volume 2, Chapter 13
12. Herzyk D.J., Gore E.R., Polsky R., Nadwodny K.L., Maier C.C., Liu S., Hart T.K., Harmsen A.G., and Bugelski P.J. Infect. Immun. 69 2 (2001) 1032-1043
13. Luebke R.W. Assessment of host resistance to infection with rodent malaria. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), WileyLiss, Inc., New York, N.Y. 221-242 Volume 2, Chapter 16
14. Van Loveren H., Luebke R.W., and Vos J.G. Assessment of immunotoxicity with the parasitic infection model Trichinella spiralis. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), Wiley-Liss, Inc., New York, N.Y. 243-271 Volume 2, Chapter 17
15. McCay J.A. Syngeneic tumor cell models B16F10 and PYB6. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), Wiley-Liss Inc., New York, N.Y. 143-157 Volume 2, Chapter 11
16. Cuff C.F., Fulton J.R., Barnett J.B., and Boyce C.S. Toxicol. Sci. 42 (1998) 99-108
17. Li M., Cuff C.F., and Pestka J. Toxicol. Sci. 87 1 (2005) 134-145
18. Selgrade M.J.K., Daniels M.J., Burleson G.R., Lauer L.D., and Dean J.H. Int. J. Immunopharmacol. 10 (1998) 811-818
19. Selgrade M.J.K., and Daniels M.J. Host resistance models: Murine cytomegalovirus. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology (1995), Wiley-Liss Inc., New York, N.Y. 203-219 Volume 2, Chapter 15
20. Ross P.S., de Swart R.L., van der Vliet H., Willemsen L., De Klerk A., Van Amerongen G., Groen J., Brouwer A., Schipholt I., Morse D.C., and van Loveren H. Arch. Toxicol. 71 9 (1997) 563-574
21. Ross P.S., van Loveren H., de Swart R.L., van der Vliet H., de Klerk A., Timmerman H.H., Van Binnendijk R., Brouwer A., Vos J.G., and Osterhaus A.d. Arch. Toxicol. 70 10 (1996) 661-671
22. Garssen J., van der Vliet H., De Klerk A., Goettsch W., Dormans J.A., Bruggeman C.A., Osterhaus A.D., and Van Loveren H. Eur. J. Pharmacol. 292 3-4 (1995) 223-231
23. Van Loveren H. Hum. Exp. Toxicol. 14 1 (1995) 137-140
24. Goettsch W., Garssen J., de Gruijl F.R., and Van Loveren H. Toxicolology 72 1-3 (1994) 359-363
25. M.C. Jordan, J.D. Shanley, and J.G. Stevens, J. Gen. Virol. 37, (2):419-423.
26. Polić B., Hengel H., Krmpotić A., Trgovcich J., Pavić I., Lučin P., Jonjić S., and Koszinowski U.H. J. Exp. Med. 188 (1998) 1047-1054
27. Wyde P.R., Couch R.B., Mackler B.F., Cate T.R., and Levy B.M. Infect. Immun. 15 1 (1977) 221-229
28. Burleson G.R., Lebrec H., Yang Y.G., Ibanes J.D., Pennington K.N., and Birnbaum L.S. Fund. Appl. Toxicol. 29 (1996) 40-47
29. Lebrec H., and Burleson G.R. Toxicology 91 2 (1994) 179-188
30. Warren T.K., Mitchell K.A., and Lawrence B.P. Toxicol. Sci. 56 (2000) 114-123
31. Mitchell K.A., and Lawrence B.P. Toxicol. Sci. 74 (2003) 74-84
32. Lawrence B.P., and Vonderstrasse B.A. Toxicol. Sci. 79 (2004) 304-314
33. Teske S., Bonn A.A., Regal J.F., Neumiller J.J., and Lawrence B.P. Am. J. Physiol. Lung Cell. Mol. Physiol. 289 1:L (2005) 111-124
34. Vonderstrasse B.A., Cundiff J.A., and Lawrence B.P. J. Toxicol. Environ. Health A 69 6 (2006) 445-463
35. Bonn A.A., Harrod K.S., Teske S., and Lawrence B.P. Chem. Biol. Interact. 155 3 (2005) 181-190
36. Kawabata T.T., Burleson G.R., Ernst P.B., and Ullrich S.E. Fund. Appl. Toxicol. 26 1 (1995) 8-19
37. Burleson G.R., Ibanes J.D., and Morgan K.T. Fund. Appl. Toxicol. 26 1 (1995) 11-19
38. Ibanes J.D., Morgan K.T., and Burleson G.R. Vet. Pathol. 33 (1996) 412-418
39. Dye J.A., Morgan K.T., Neldon D.L., Tepper J.S., Burleson G.R., and Costa D.L. Vet. Pathol. 33 (1996) 43-54
40. Isaacs A., and Lindenmann J. Proc. R. Soc. London Ser. B 147 (1957) 258-267
41. Finter N.B. J. Exp. Pathol. 47 (1996) 361-371
42. Finter N.B. J. Gen. Virol. 1 (1967) 395-397
43. Gresser I., Tovey M.G., Bandu M.-T., Maury C., and Brouty-Boye D. J. Exp. Med. 144 (1976) 1305-1315
44. Gresser I., Tovey M.G., Maury C., and Bandu M.-T. J. Exp. Med. 144 (1976) 1316-1323
45. Hoshino A., Takenaka H., Mizukoshi O., Imanishi J., Kishida T., and Tovey M.G. Antiviral. Res. 3 (1983) 59-65
46. Wyde P.R., Wilson M.R., and Cate T.R. Infect. Immun. 38 (1982) 1249-1255
47. D.M. Hammerbeck, G.R. Burleson, C.J. Schuller, J.P. Vasilakos, M. Tomai, E. Egging, F.R. Cochran, S. Woulfe, R.L. Miller, Antiviral Research 2006, (in press).
48. Hennet T., Ziltener H.J., Frei K., and Peterhans E. J. Immunol. 149 (1992) 932-939
49. Kaiser L., Fritz R.L.S., Straus S.E., Gubareve L., and Hayden F.G. J. Med. Virol. 64 (2001) 262-288
50. Lemercier G., and Mavet S. Ann. Microbiol. (Instit. Pasteur.) 130B (1979) 235-244
51. Webster R.G., and Askonas B.A. Eur. J. Immunol. 10 (1980) 396-401
52. Ochiai H., Kurokawa M., Hayashi K., and Niwayama S. J. Virol. 62 (1988) 20-26
53. Burleson G.R. Alteration of cellular interactions in the immune system: Natural killer activity and N lymphocytes. In: Milman H.A., and Elmore E. (Eds). Biochemical Mechanisms and Regulation of Intercellular Communication. In: Mehlman M.A. (Ed). Advances in Modern Environmental Toxicology vol. XIV (1987), Princeton Scientific Publishing Co. Inc., Princeton, New Jersey 51-96
54. Van Loveren H., Krajnc E.I., Rombout P.J.A., Blommaert F.A., and Vos J.G. Toxicol. Appl. Pharmacol. 102 (1990) 21-33
55. Burleson G.R., and Keyes L.L. Immunopharmacol. Immunotoxicol. 11 (1989) 421-443
56. Burleson G.R., Keyes L.L., and Stutzman J.D. Immunopharmacol. Immunotoxicol. 11 (1989) 715-735
57. Ehrlich J.P., Gunnison A.F., and Burleson G.R. Inhal. Toxicol. 1 (1989) 129-138
58. Zinkernagel R.M., and Doherty P.C. Nature (London) 251 (1974) 547-548
59. Yap K.L., and Ada G.L. Scand. J. Immunol. 7 (1978) 73-80
60. Yap K.L., Ada G.L., and McKenzie I.F.C. Nature 273 (1978) 238-240
61. Wells M.A., Ennis F.A., and Daniel S. J. Gen. Virol. 43 (1979) 685-690
62. Wells M.A., Albrecht P., and Ennis F.A. J. Immunol. 126 (1981) 1036-1041
63. Kris R.M., Yetter R.A., Cogliano R., et al. Immunology 63 (1988) 349-353
64. Sangster M.Y., Riberdy J.M., Gonzalez M., Topham D.J., Baumgarth N., and Doherty P.C. J. Exp. Med. 198 (2003) 1011-1021
65. Burns W., Billups L.C., and Notkins A.L. Nature 256 (1975) 654-656
66. Iwasaki T., and Nozima T. J. Immunol. 118 (1977) 256-263
67. Scherle P.A., and Gerhard W. J. Exp. Med. 164 (1986) 1114-1128
68. Virelizier J.-L. J. Immunol. 115 (1975) 434-439
69. Schulman J.L., Khakpour M., and Kilbourne E.D. J. Virol. 2 (1968) 778-786
70. Jones P.D., and Ada G.L. J. Virol. 60 (1986) 614-619
71. Scott G.H., and Walker J.S. Infect. Immun. 13 (1976) 1525-1527
72. Renegar K.B., and Small Jr. P.A. J. Immunol. 146 (1991) 1972-1978